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Themammalian gastrointestinal tract is home to a dense community of resident bacteria and is also exposed
tomicroorganisms from the external environment. The epithelial surface of the intestine plays a critical role in
host protection by producing a diverse repertoire of antimicrobial proteins that directly kill or hinder the
growth of microorganisms. Here we discuss the general principles that govern the mechanisms of action
of epithelial antimicrobial proteins, regulation of antimicrobial protein expression and activity, and in vivo
functions of intestinal antimicrobial proteins. We also consider how altered antimicrobial protein expression
and function can contribute to disease and how these endogenous antibiotics might be harnessed for the
benefit of human health.Introduction
Interactions with the microbial world are a fact of life for nearly all
animals and plants. As a consequence, multicellular organisms
throughout phylogeny have evolved immune-defense mecha-
nisms that confer protection against bacteria, viruses, fungi,
and parasites. Antimicrobial proteins (AMPs), which rapidly kill
or inactivate microorganisms, constitute one of the most evolu-
tionarily ancient mechanisms of immune defense. A diverse
array of AMPs are made by nearly all multicellular organisms,
including plants, insects, fish, and mammals.
In mammals, themajority of AMPs are produced by the epithe-
lial surfaces of tissues that interface directly with the environ-
ment, including the intestine, skin, respiratory tract, and repro-
ductive tract. Each of these tissues frequently encounters a
diversity of microorganisms that can cause disease. In addition,
such body sites also are associated with a resident microbiota
composed largely of commensal microorganisms. Thus, surface
tissues are faced with the enormous challenge of maintaining
homeostasis with complex assemblies of commensal bacteria
while also limiting pathogen invasion.
Nowhere is this challenge more pronounced than in the
mammalian intestine, which is home to a diverse community
of indigenous microorganisms numbering in the trillions. The
organisms of the intestinal microbiota make substantial con-
tributions to host metabolism while being provided with a
nutrient-rich environment in which to live and multiply. Although
the relationship between mammals and their intestinal micro-
biota is mutually beneficial, the enormous numbers of intestinal
bacteria present a continuous threat of barrier breach, and the
large surface area of the intestine (200 m2 in humans) com-
pounds this threat.
In order tomeet these challenges, the epithelial surfaces of the
intestine produce an abundance of AMPs. The diversity of intes-
tinal AMPs most likely reflects the complexity of the microbial
challenges faced by intestinal epithelial cells and the continuous
threat of microbial invasion. Here we present an integrated view
of how epithelial AMPs defend the intestine. We will discuss the
molecular mechanisms that underlie the antimicrobial activity
of intestinal AMPs, examine the regulatory mechanisms that
govern AMP expression and function, and explore how epithelial28 Immunity 42, January 20, 2015 ª2015 Elsevier Inc.AMPs defend intestinal tissues in vivo. Finally, we will highlight
the potential of endogenous AMPs as therapeutic antibiotics
and consider how impaired AMP function can contribute to in-
testinal disease.
Molecular Mechanisms of AMP Antimicrobial Activity
Many intestinal AMPs mediate killing by attacking the basic cell-
wall structures of bacteria. Bacterial cell walls include the mem-
brane, peptidoglycan layer, and in Gram-negative bacteria, the
outer membrane. The evolutionary rationale for targeting essen-
tial cell-wall structures lies in the fact that such structures are
difficult for microorganisms to modify without a consequent
loss in overall fitness. This reduces the likelihood that bacteria
will develop resistance to such AMPs.
Several epithelial AMPs kill bacteria through enzymatic attack
on key structures of the cell wall. One such protein, lysozyme, is
produced by Paneth cells, a specialized secretory cell lineage of
the intestinal epithelium. Lysozyme is a glycosidase that hydro-
lyzes the 1,4-b-glycosidic linkages between the N-acetylglucos-
amine and N-acetylmuramic acid moieties of peptidoglycan.
Consequently, lysozyme is more effective against Gram-positive
bacteria, where the peptidoglycan is more accessible, than
against Gram-negative organisms, where the peptidoglycan is
cloaked by the outer membrane (Ganz, 2004).
In addition to directly killing bacteria, lysozyme enzymatic
activity can regulate downstream innate immune responses to
certainmicroorganisms. Themucosal pathogenStaphylococcus
aureus typically activates the multiprotein inflammasome com-
plex, which mediates processing and maturation of the proin-
flammatory cytokine IL-1b. Interestingly, lysozyme-mediated
degradation of peptidoglycan is essential for S. aureus-induced
inflammasome activation and IL-1b secretion. Thus, lysozyme-
mediated peptidoglycan degradation can be coupled to inflam-
masome activation and the ensuing inflammatory response
(Shimada et al., 2010).
Secretory phospholipase A2 (sPLA2) is a second example of an
epithelial AMP that kills bacteria through an enzymatic mecha-
nism. Like lysozyme, sPLA2 is produced abundantly by Paneth
cells (Harwig et al., 1995; Vadas et al., 1993). sPLA2 penetrates
the bacterial cell wall to gain access to the membrane (Beers
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Figure 1. Models of Bacterial Membrane Permeabilization by Key Intestinal AMPs
Several epithelial AMPs of the intestine kill bacteria by disrupting their membranes. Biophysical and structural approaches have produced detailed insight into the
mechanisms of membrane permabilization.
(A) a-defensin, expressed as an inactive propeptide, is processed to the active protein by matrix metalloproteinase 7 (MMP7) in mice and by trypsin in humans
(Ghosh et al., 2002;Wilson et al., 1999). Solid-state NMR studies suggest that a-defensins permeabilize the bacterial membrane by forming a dimer pore, which is
stabilized by electrostatic interactions between defensin cationic residues and anionic phospholipid headgroups on the bacterial membrane (Zhang et al., 2010).
(B) Inactive pro-REG3a/g is converted to the active form by trypsin-dependent proteolytic processing (Mukherjee et al., 2009). REG3a kills Gram-positive bacteria
by first binding to peptidoglycan, then oligomerizing to form a hexameric membrane-penetrating pore that is stabilized by electrostatic interactions between
REG3a cationic residues and the anionic phospholipids of the bacterial membrane (Mukherjee et al., 2014).
(C) Cathelicidins such as LL-37 first bind to bacterial membranes via electrostatic interactions. In aqueousmedia the structure of LL-37 is disordered, but it adopts
an a-helical secondary structure in the presence of lipids. Biophysical studies in model membranes predict that the a-helix initially orients itself parallel to the lipid
bilayer and then inserts into themembrane by forming toroidal pores inwhich the pore is lined by both the inserted peptide and the phospholipid headgroups (Bals
and Wilson, 2003; Zanetti, 2005).
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promises bacterial membrane integrity (Koprivnjak and Peschel,
2011).
A number of epithelial AMPs kill bacteria through non-enzy-
matic mechanisms of cell-wall attack. These include the mem-
bers of key AMP families such as defensins, C-type lectins of
the REG3 family, and cathelicidins. Most of these AMPs disrupt
bacterial membranes, leading to breakdown of membrane po-
tential, loss of metabolites and ions, and osmotic lysis (Brogden,
2005). In doing so, such proteins exploit unique features of bac-
terial membranes relative to eukaryotic membranes. Bacterial
cell membranes are composed mainly of acidic phospholipids
such as phosphatidylglycerol and cardiolipin (Matsuzaki, 1999)
and thus have a net negative charge. Eukaryotic membranes,
by contrast, are asymmetric and carry negatively charged phos-
pholipids only in the inner leaflet of the cell membrane, facing the
cytoplasm. Defensins, REG3 lectins, and cathelicidins all have a
net positive charge and thus interact with the bacterial mem-
brane through electrostatic interactions (Du¨rr et al., 2006; Fujii
et al., 1993; Mukherjee et al., 2014). The requirement for electro-
static interactions with negatively charged phospholipid head-
groups also helps to limit potentially detrimental interactions
with host cell membranes.
Other intestinal epithelial AMPs mediate their antibacterial
effects by interfering with bacterial cell wall synthesis. For
example, human b-defensin 3 binds to the peptidoglycan
precursor lipid II, thereby perturbing the cell-wall biosynthesismachinery. This results in localized cell wall lesions that lead to
osmotic rupture of the bacteria under low-salt conditions (Sass
et al., 2010). Other organisms, such as fungi, also produce de-
fensins that act through a similar mechanism (Schneider et al.,
2010).
Mechanistic Insights into Membrane Permeabilization
by Epithelial AMPs
Upon binding to the bacterial membrane, defensins, lectins, and
cathelicidins each use distinctive mechanisms to disrupt mem-
brane integrity (Figure 1). Insight into these mechanisms has
come from detailed biochemical, biophysical, and structural
studies of each of these AMP families.
Defensins represent one of the first families of membrane-dis-
rupting AMPs discovered in mammals. These small proteins
range in size from 2–4 kDa and have broad-spectrum microbici-
dal activity against Gram-positive and Gram-negative bacteria,
fungi, protozoa, and enveloped viruses (Selsted and Ouellette,
2005; Wilson et al., 2013). Defensin primary sequences include
conserved cysteine residues that form disulfide bridges, creating
a three-dimensional structure that is conserved among family
members (Ganz, 2004). Based on their disulfide-bond arrange-
ment and cysteine-residue spacing, defensins are classified
into three major groups, denoted a, b, and q (Selsted and Ouel-
lette, 2005).
a-defensins, including HD5 and HD6 in humans and cryptdins
1–16 in mice, are expressed exclusively in Paneth cells of theImmunity 42, January 20, 2015 ª2015 Elsevier Inc. 29
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tinal AMPs (Selsted and Ouellette, 2005). Mouse defensins
are termed cryptdins because of their localization within small in-
testinal crypts (mucosal invaginations of the small intestine that
harbor Paneth cells). Mice also produce a family of diverse crypt-
din-related sequence peptides in the intestine. These peptides
homodimerize or heterodimerize by forming intermolecular di-
sulfide bridges, which confer increased potency against both
Gram-positive and Gram-negative bacteria (Hornef et al., 2004).
b-defensins, by contrast, are expressed throughout the
epithelium in both the small and large intestines (O’Neil et al.,
1999). Eight of the 28 b-defensins encoded in the human genome
are expressed in intestinal epithelial cells (Fahlgren et al., 2003;
Wehkamp et al., 2002). The expression of q-defensins is
restricted to leukocytes and bonemarrow of OldWorld monkeys
(Ganz, 2003).
Structural analysis of the defensins provides insight into how
they interact with bacterial membranes. X-ray crystallography
of multiple a-defensins (including HNP3, HNP4, and HD5) re-
veals a three-dimensional structure that is dimeric and basket-
shaped and has a characteristic amphipathic arrangement with
a polar top and an apolar base (Hill et al., 1991; Szyk et al.,
2006). This arrangement produces a positively charged surface
that is spatially separated from neighboring hydrophobic re-
gions, thus facilitating insertion into negatively chargedmicrobial
membranes. The hydrophobic regions are predicted to be buried
in the lipid interior, whereas the cationic residues engage in elec-
trostatic interactions with the anionic phospholipid headgroups
on the bacterial membrane. The dimers of certain a-defensins,
such as human a-defensin 6 (HD6), can also self-associate to
form higher-order oligomers, resulting in long filaments that are
observed in vivo (Chu et al., 2012).
Careful biophysical studies of defensins in association with
artificial lipid bilayers indicate that they form membrane-pene-
trating pores, or channels, that conduct ions (Kagan et al.,
1990; Madison et al., 2007). Although the structural details of
the assembled pores remain to be determined, solid-state nu-
clear magnetic resonance (NMR) analysis of a human a-defensin
(HNP-1) has provided information about the oligomeric state and
topology of a-defensins in lipid bilayers (Zhang et al., 2010).
Because a-defensins are anchored by three disulfide bonds
that impart a high degree of conformational rigidity, major sec-
ondary structure changes upon lipid binding are restricted.
This is in contrast to many other membrane-toxic proteins, for
which membrane insertion is accompanied by major secondary
structural transitions (Brogden, 2005). The NMR data suggest
that HNP-1 adopts a ‘‘dimer pore’’ topology in which the polar
top faces the aqueous pore and the hydrophobic bottom inter-
faces with the lipid chains.
The antimicrobial properties of some defensins might rely on
mechanisms other than direct bacterial killing. For example,
HD6 oligomerizes to form long fibrils that can entrap bacteria
at the intestinal mucosal surface and prevent their translocation
across the epithelial barrier (Chu et al., 2012). In contrast to other
a-defensins, HD6 lacks direct bactericidal activity when its six
cysteines are oxidized to form three intramolecular disulfide
bonds (Chairatana and Nolan, 2014; Chu et al., 2012; Schroeder
et al., 2014). However, in a reducing environment that mimics
that of the intestinal lumen, the HD6 disulfide bonds are reduced,30 Immunity 42, January 20, 2015 ª2015 Elsevier Inc.and the peptide acquires a conventional antimicrobial activity
that results in cell-wall disruption (Schroeder et al., 2014). It
seems likely that both mechanisms account for the efficacy of
HD6 against bacteria in vivo.
REG3g and its human ortholog, REG3a (also known as hepa-
tocarcinoma intestine-pancreas/pancreatic associated protein,
or HIP/PAP) are soluble lectins expressed throughout the small
intestinal epithelium (Cash et al., 2006a; Christa et al., 1996).
Expression of REG3g is also inducible by injury in the skin (Lai
et al., 2012) and by inflammatory signals in upper-respiratory-
tract epithelial cells of mice (Choi et al., 2013). In the small intes-
tine, REG3 lectins are secreted apically into the lumen, where
they contact intestinal bacteria (Cash et al., 2006b).
Biochemical and biophysical studies of human REG3a have
yielded detailed insight into the bactericidal mechanism of
REG3 C-type lectins. Initial interactions between REG3a and
its bacterial targets are mediated by binding to peptidoglycan
(Cash et al., 2006b; Lehotzky et al., 2010). REG3 bactericidal ac-
tivity is therefore selective for Gram-positive bacteria because
peptidoglycan is generally accessible on the outer surfaces of
Gram-positive bacteria but is shielded by the outer membrane
in Gram-negative bacteria (Cash et al., 2006b). Peptidoglycan
binding is mediated by interactions between a Glu-Pro-Asn
(EPN) motif, located in the long loop region of REG3a, and the
carbohydrate moiety of peptidoglycan (Lehotzky et al., 2010).
Importantly, REG3 recognition of peptidoglycan involves a
unique mechanism that allows high-affinity binding to the ex-
tended carbohydrate chains of surface peptidoglycan but not
to shorter, soluble peptidoglycan chains. This allows selective
binding to the bacterial surface while avoiding competitive inhi-
bition by shorter peptidoglycan chains that are shed by bacteria
and are thus abundant in the intestinal environment (Lehotzky
et al., 2010).
Although peptidoglycan binding is essential for bacterial
recognition by REG3a, bacterial killing requires additional activ-
ities. A second distinct step in the REG3a bactericidal mecha-
nism involves permeabilization of the bacterial membrane. As
with defensins, cationic REG3a residues mediate initial interac-
tions with the negatively charged bacterial membrane (Mukher-
jee et al., 2014). Although monomeric in aqueous solution,
REG3a oligomerizes upon contact with lipids to form hexameric
transmembrane pores. The pores are permeable to ions and
small dyes and are essential for the bactericidal activity of
REG3a (Mukherjee et al., 2014). Importantly, the introduction of
specific point mutations that inactivate peptidoglycan binding
or membrane permeabilization demonstrate that these two ac-
tivities are mediated by distinct REG3a protein domains and
can be uncoupled (Lehotzky et al., 2010; Mukherjee et al.,
2014; 2009). Thus, bacterial binding and membrane permeabili-
zation are distinct REG3a activities that are each essential for
bactericidal activity.
Structural approaches, including cryo-electron microscopy
and X-ray crystallography, have allowed construction of a
detailed three-dimensional model of the hexameric REG3a
pore assembly (Mukherjee et al., 2014). The REG3a hexameric
pore is formed by three REG3a dimers that are helically symmet-
rical. The pore is stabilized in the lipid bilayer by charge-charge
interactions between REG3a cationic residues and the ani-
onic phospholipids of the bacterial membrane. Physics-based
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charged lipid molecules collect around the positively charged
residues on the outer surface of the pore complex and that this
results in a favorable negative free energy for REG3a hexamer
insertion into the membrane (Mukherjee et al., 2014).
At least two features of the REG3a pore model are distinctive
relative to other structurally well-characterized protein pores.
First, oligomerization of REG3a in themembrane bilayer appears
to occur without any pronounced secondary structural changes
in the protein (Mukherjee et al., 2014). Like the structure of de-
fensins, the REG3a three-dimensional structure is anchored by
three disulfide bonds, imparting a high degree of structural rigid-
ity that most likely precludes major secondary-structure transi-
tions. This is in contrast to many other less-rigid pore-forming
proteins (e.g., pneumolysin, nisin, and gramicidin), for which
membrane insertion follows major changes in secondary struc-
ture (Brogden, 2005). Second, the structural model of the
REG3a pore suggests that small numbers of positively charged
residues are buried in the membrane interior (Mukherjee et al.,
2014). Although the energetic cost of basic residue insertion is
predicted to be high, a similar situation exists with the human
a-defensin HNP-1; positively charged Arg residues of HNP-1
are predicted to localize to the membrane interior (Zhang et al.,
2010). It is worth noting that there are now multiple examples
of integral membrane proteins or membrane-penetrating pro-
teins that contain lipid-facing positively charged residues des-
pite the energetic costs (Bass et al., 2002; Jiang et al., 2003).
Membrane-damaging lectins most likely represent a general
mechanism of antibacterial defense at mucosal surfaces.
REG3b, which is closely related to mouse REG3g and human
REG3a, is usually co-expressed with REG3g in mice (Cash
et al., 2006b; Vaishnava et al., 2008). Recent studies suggest
that REG3b binds to carbohydrate moieties on LPS and thus kills
Gram-negative bacteria (Miki et al., 2012; Stelter et al., 2011).
Galectins represent another branch of the lectin family whose
members have antibacterial functions. Galectin-4 and Galec-
tin-8 are expressed in the gastrointestinal tract and specifically
bind and kill Escherichia coli strains having surface carbohydrate
structures that mimic human blood-group antigens. Bacterial
killing is accompanied by disruption of the bacterial membrane
(Stowell et al., 2010), although themechanism of membrane per-
meabilization remains to be defined. It is possible that these
bactericidal lectins evolved to target pathogens that otherwise
would evade the adaptive immune system through mimicry of
host antigenic structures.
Cathelicidins are a third class of epithelial antimicrobial pep-
tides that kill microorganisms by membrane disruption (Bals
and Wilson, 2003). Like defensins and REG3 lectins, they are
cationic, but they differ structurally in that they are a-helical pep-
tides with a conserved 14 kDa N-terminal ‘‘cathelin’’ (cathepsin L
inhibitor)-like domain and a variable C-terminal region. Cathelici-
dins are expressed in epithelial cells of the small and large intes-
tines and the skin (Gallo et al., 1994; Hase et al., 2002). The single
cathelicidin gene (CAMP in humans) encodes a precursor pro-
tein (hCAP18) (Larrick et al., 1996) that can be cleaved at an
alternate site to generate several active AMPs, including the
37-amino acid peptide LL-37 (Gudmundsson et al., 1996) and
the murine peptide CRAMP (cathelin-related antimicrobial pep-
tide) (Gallo et al., 1997). Both LL-37 and CRAMP exhibit broad-spectrum antimicrobial activity against Gram-positive and
Gram-negative bacteria, as well as fungi (Travis et al., 2000).
The initial interactions of cathelicidins with membranes are
broadly similar to those of defensins and REG3 lectins. They kill
bacteriabyfirstbinding tobacterialmembranesviacharge-charge
interactions, followed bymembrane insertion and disruption (Bals
and Wilson, 2003). In aqueous media the structure of LL-37 is
disordered, whereas in the presence of lipids, LL-37 adopts an
a-helical secondary structure; the extent of helicity is proportional
to the antibacterial activity (Duplantier and van Hoek, 2013). Bio-
physical studies in model membranes suggest that during mem-
branedisruption, theamphipathichelix initiallyorients itselfparallel
to the lipid bilayer. The LL-37 helices ultimately assimilate into the
membrane as a toroidal pore, which is formed when the lipid
monolayers bend such that the aqueous pore is lined by both
the inserted peptide and the lipid headgroups (Zanetti, 2005).
The molecular mechanisms underlying the antibacterial activ-
ity of other intestinal microbicidal proteins remain unclear. An-
giogenin-4 (ANG4) is a ribonuclease family member that is
expressed exclusively in Paneth cells. ANG4 has broad-spec-
trumbactericidal activity against Gram-positive andGram-nega-
tive bacteria (Hooper et al., 2003) and is thus similar to other
bactericidal RNases, including RNase 7 (Harder and Schroder,
2002) and eosinophil cationic protein (Rosenberg, 1995).
Although ANG4 has RNase activity, it remains unclear whether
this enzymatic activity is required for bactericidal function.
Altogether, several distinct families of AMPswork in concert to
defend the epithelial surfaces of mammalian barrier tissues.
Despite their widely divergent primary sequences, several of
these AMP families have converged on similar mechanisms of
microbial killing through membrane disruption.
Transcriptional Regulation of Epithelial AMPs
AMPs that disrupt bacterial membranes are frequently also toxic
to mammalian membranes. Consequently, the expression,
secretion, and activity of epithelial AMPs are tightly controlled
through multiple transcriptional and post-translational mecha-
nisms (Figure 2).
Studies of germ-free mice have revealed that some intestinal
epithelial AMPs are expressed independently of microbial sig-
nals, whereas others require microbial stimulation for normal
expression. Intestinal a-defensins are expressed under the con-
trol of the WNT pathway transcription factor TCF4 (van Es et al.,
2005) but are produced independently of microbial signals (Put-
sep et al., 2000). Similarly, lysozyme, sPLA2 and some members
of the b-defensin family are expressed independently of the mi-
crobiota (Hooper et al., 2001; 2003; O’Neil et al., 1999). Although
the epithelial cathelicidin LL-37 is expressed in the absence of
bacteria, its expression is modestly upregulated by invasive mi-
croorganisms (Hase et al., 2002).
Other intestinal AMPs require microbial stimulation for full
expression. Members of the cryptdin-related sequence family
of peptides show increased expression in conventionally-raised
mice compared with germ-free mice (Putsep et al., 2000). Simi-
larly, certain members of the human b-defensin family, including
hBD2, show elevated expression in the presence of bacteria
(O’Neil et al., 1999). Finally, expression of both ANG4 and
REG3g is low in germ-free mice but markedly increases after
bacterial colonization (Cash et al., 2006b; Hooper et al., 2003).Immunity 42, January 20, 2015 ª2015 Elsevier Inc. 31
Figure 2. Regulation of AMP Expression, Secretion, and Activity
AMPs are tightly controlled through multiple transcriptional and post-translational mechanisms.
Regulation of AMP gene expression: In the small intestine, the transcription factor TCF4 governs a-defensin expression (van Es et al., 2005). This expression is
generally independent of bacterial signals. In contrast, Reg3g transcription is controlled by microbe-associated molecular patterns (MAMPs), such as lipo-
polysaccharide (LPS), through the Toll-like receptor (TLR)-MYD88 signaling pathway (Brandl et al., 2007; Vaishnava et al., 2008; 2011). Reg3g expression also
requires interleukin-22 (IL-22) from innate lymphoid cells (Sanos et al., 2011).
Regulation of granule exocytosis: The process of AMP secretion is regulated by bacterial signals (Ayabe et al., 2000) as well as autophagy-pathway proteins, such
as ATG16L1. ATG16L1 controls granule formation in Paneth cells, and humans harboring a polymorphic variant of ATG16L1 exhibit abnormal Paneth-cell granule
formation (Cadwell et al., 2008).
Post-translational regulation: Like other membrane-permeabilizing AMPs, REG3 lectins can be toxic to host cell membranes and are therefore stored as inactive
propeptides inside epithelial-cell secretory granules. After secretion, pro-REG3a is proteolytically processed to its active form by trypsin (Mukherjee et al., 2009).
The REG3a pore complex self-assembles into long filaments that also regulate REG3a membrane toxicity. These macromolecular structures may function to
sequester excess membrane-active REG3a pores and thereby limit toxicity toward host membranes (Mukherjee et al., 2014).
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some bacterially regulated epithelial AMPs. Toll-like receptors
(TLRs) are membrane-bound pattern-recognition receptors that
play a central role in microbial pattern recognition in mammals.
TLRs bind to conserved microbial molecules, or ‘‘molecular pat-
terns,’’ that are unique to viruses or bacteria but are lacking in
mammaliancells.Binding triggerssignalingcascades thatactivate
nuclear factor kB (NFkB), which in turn drives transcription of
proinflammatory cytokines and AMPs (Ronald and Beutler, 2010).
TLR stimulation is required for REG3g expression by intestinal
epithelial cells. REG3g expression is markedly lower in mice
lacking epithelial cell expression of myeloid differentiation pri-
mary response protein 88 (MYD88), an adaptor molecule that
transduces signals downstream of several TLRs (Brandl et al.,
2007; Vaishnava et al., 2008; 2011). This suggests that epithelial
TLRs are required for full REG3g expression. The requirement for
the TLR-MYD88 pathway is consistent with the fact that both
LPS and flagellin (which activate TLR4 and TLR5, respectively)
can stimulate REG3g expression (Brandl et al., 2007; Kinnebrew
et al., 2010; Vaishnava et al., 2008).
Intestinal epithelial cell expression of REG3g mRNA also re-
quires cytokine signals from innate lymphoid cells (ILCs), a sub-32 Immunity 42, January 20, 2015 ª2015 Elsevier Inc.epithelial immune cell lineage (Sanos et al., 2009). Certain ILC
subsets produce the cytokine interleukin22 (IL22), which binds
to IL22 receptors on epithelial cells and modulates epithelial
cell function (Goto et al., 2014; Pham et al., 2014; Pickard
et al., 2014; Wolk et al., 2004). ILC-derived IL22 is required for
epithelial cell expression of REG3g mRNA (Sanos et al., 2009).
Thus, REG3g expression is dependent on both epithelial cell
intrinsic TLR-MYD88 signaling and IL22 produced by ILCs. It is
not yet clear why REG3g expression requires a complex regula-
tory network involving multiple cell types. One possibility is that
IL22 licenses epithelial cells for REG3g expression, but epithelial
cellsmust then receive a bacterial signal through TLRs in order to
express REG3g.
There is some evidence that antimicrobial functions of the
small intestine are also regulated by NOD2, an intracellular
pattern-recognition receptor. NOD2-dependent signaling re-
quires activation by muramyl dipeptide (MDP), a peptidoglycan
component that is common to Gram-positive and Gram-nega-
tive bacteria (Girardin et al., 2003). Although the exact mecha-
nisms remain to be defined, NOD2 enhances the bactericidal
activity of Paneth cells (Petnicki-Ocwieja et al., 2009), modu-
lates the composition of the microbiota in the small intestine
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tects against oral challenge with the pathogen Listeria monocy-
togenes (Kobayashi et al., 2005). NOD2 has been reported to
regulate the expression of certain a-defensins (Kobayashi
et al., 2005), but subsequent studies have indicated that a-de-
fensin expression is independent of NOD2 when the mouse ge-
netic background is carefully controlled (Shanahan et al., 2014).
Together, these findings establish that the transcriptional
regulation of different subsets of AMPs occurs through distinct
mechanisms. AMPs that do not depend on bacterial cues prob-
ably form a constitutive chemical barrier at the mucosal surface.
Bacterial induction of other AMPs could ensure that the inducible
AMPs are produced only when needed, thus limiting the possibil-
ity that these AMPs could unnecessarily alter intestinal microbial
composition or compromise the beneficial contributions of the
microbiota.
Post-Translational Regulation of Epithelial AMPs
The functions of membrane-toxic AMPs are generally sup-
pressed during storage inside membrane-bound secretory
vesicles because these AMPs can also damage host cell mem-
branes (Lichtenstein et al., 1986). Both a-defensins and REG3
lectins are stored as inactive propeptides inside epithelial-
cell secretory granules. In mice, matrix metalloproteinase-7
(MMP7) processes pro-a-defensins at their N termini to yield
active proteins (Wilson et al., 1999). In contrast, human pro-
a-defensins and mouse and human REG3 lectins are proteolyti-
cally processed by trypsin to produce mature, bactericidally
active proteins (Ghosh et al., 2002; Mukherjee et al., 2009). Cath-
elicidins are similarly expressed as propeptides, but the pro-
cessing mechanism in the intestine is unknown (Schutte and
McCray, 2002). It is not yet clear whether b-defensins are ex-
pressed as propeptides, and thus the mechanisms regulating
their membrane-damaging activity inside host cells are unclear.
The distinctive reducing environment of the intestinal lumen
underpins another mechanism that protects host cells during
AMP storage. In the presence of oxidizing conditions that are
typically found inside host cells, human b-defensin 1 (hBD1)
has minimal antimicrobial activity. However, upon contact with
a reducing environment that mimics conditions in the intestinal
lumen, hBD1 undergoes marked conformational changes that
unmask a potent antimicrobial activity (Schroeder et al., 2011).
Filamentation might represent yet another mechanism that
regulates AMP activity. The formation of higher-order filamen-
tous assemblies is frequently observed for mammalian mem-
brane toxic proteins in other tissue contexts, such as the brain
and the nervous system (Butterfield and Lashuel, 2010; Kagan
et al., 2012). Interestingly, the ability to form long filaments is
observed for both REG3a and HD6, suggesting that filamenta-
tion might also be a characteristic of membrane-toxic intestinal
AMPs. In the case of REG3a, the filaments are higher-order
macromolecular assemblies of REG3a pore complexes, and
filamentation inhibits the membrane toxicity and bactericidal ac-
tivity of REG3a (Mukherjee et al., 2014). This suggests that fila-
mentation might sequester the membrane-active REG3a pores
and thus limit excessive membrane-permeabilizing activity to-
ward the intestinal epithelial surface once a microbial threat
has been eliminated. In the case of HD6, the filaments ensnare
bacteria in ‘‘nanonets’’ and are thus important for antimicrobialfunction (Chu et al., 2012). It will be interesting to determine
whether HD6 filamentation also inhibits conventional antimicro-
bial activity (Schroeder et al., 2014).
Regulation of Epithelial AMP Secretion
The process of AMP secretion is also controlled by bacterial sig-
nals. Most AMPs in the small intestine are produced by Paneth
cells, which secrete the contents of granules containing multiple
AMPs, including a-defensins, ANG4, and lysozyme. Experi-
ments performed on isolated mouse small-intestinal crypts
showed that Paneth cells discharge their granule contents
when the crypts are exposed to live bacteria or to bacterial mol-
ecules such as LPS (Figure 2) (Ayabe et al., 2000). This sug-
gested that microbial signals might act directly on Paneth cells
to induce degranulation. However, recent studies on primary
epithelial organoids have suggested that Paneth-cell degranula-
tion occurs in response to cytokines secreted by immune cells in
the surrounding milieu. These organoids, which are purely
epithelial, are refractory to bacterial stimuli unless cultured with
immune-cell-derived supernatants that contain interferon g
(Farin et al., 2014).
Proteins of the autophagy pathway also regulate granule
exocytosis in Paneth cells. ATG16L1 and ATG5 are proteins
that participate in autophagy, a cellular process that targets
cytoplasmic materials to the lysosome for degradation. Both
proteins are also essential for normal Paneth-cell granule pack-
aging and exocytosis and are thus critical for intestinal AMP
release (Cadwell et al., 2008). In humans, individuals harboring
a polymorphic variant of ATG16L1 exhibit abnormal Paneth-
cell granule formation and are at elevated risk for intestinal in-
flammatory disease (Cadwell et al., 2008).
In Vivo Functions of Epithelial AMPs
It has long been thought that the diverse arsenal of intestinal
AMPs evolved in response to the large numbers of microorgan-
isms that are encountered at these sites. Studies of genetically
engineered mouse models have offered concrete insight into
the in vivo biological functions of epithelial AMPs. Such studies
have shown that AMPs performmultiple functions, including pro-
tecting against pathogen colonization and controlling microbiota
composition and location.
Studies of mice with altered AMP function show that some
AMPs confer protection against enteric bacterial pathogens.
As discussed above, MMP-7 processes mouse pro-a-defensins
so that they acquire their active forms and is therefore essential
for a-defensin antimicrobial activity. Mmp7/ mice exhibit
enhanced susceptibility to oral challenge with Salmonella typhi-
murium, suggesting that fully functional a-defensins are required
for mucosal protection against intestinal bacterial pathogens
(Wilson et al., 1999). Supporting this idea, transgenic mice that
overexpress human a-defensin-5 (DEFA5) in Paneth cells show
greater resistance to oral S. typhimurium challenge than wild-
type mice (Salzman et al., 2003). Finally, antibody-mediated
inactivation of REG3g reveals a role for REG3g in limiting coloni-
zation by intestinal pathogens such as Listeria monocytogenes
and vancomycin-resistant Enterococcus faecalis (Brandl et al.,
2007; 2008).
a-defensins also regulate the composition of commensal bac-
terial communities in the intestinal lumen. Mmp7/ and DEFA5Immunity 42, January 20, 2015 ª2015 Elsevier Inc. 33
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composition, suggesting that a-defensins play a role in dictating
the structure of the bacterial community in the intestine (Salzman
et al., 2010). The bacterial-community changes in DEFA5 trans-
genic mice coincide with altered frequencies of certain adaptive
immune cells, such as T helper 17 (Th17) cells (Salzman et al.,
2010). This is consistent with the fact that Th17 cell development
is sensitive to microbiota composition (Ivanov et al., 2009). Thus,
a-defensins play an important role in shaping intestinal micro-
biota composition and thus in controlling the amount of immune
stimulation.
AMPs are also involved in restricting access of the intestinal
microbiota to host tissues. The surface of the mammalian intes-
tine is covered by a 150-mm-thick mucus layer that acts as
a physical barrier against luminal bacteria (Johansson et al.,
2008) and concentrates AMPs near the epithelial surface
(Meyer-Hoffert et al., 2008). Studies of Reg3g/ mice indicate
that REG3g is one AMP that is especially important
for enforcing the physical separation of microbiota and host
(Loonen et al., 2014; Vaishnava et al., 2011) and for limiting
microbiota activation of adaptive immunity (Vaishnava et al.,
2011). REG3g thus promotes host-bacterial mutualism by regu-
lating the spatial relationships between microbiota and host.
Evolution of Resistance to AMPs
Bacterial resistance to commercially available small-molecule
antibiotics has become a global public-health concern. The
worldwide emergence of antibiotic-resistant bacteria has raised
the specter of a post-antibiotic era where common infections
and minor injuries can become life threatening. In the past two
decades, such resistance has led to the evolution of multi-
drug-resistant bacteria that cause serious infections in immuno-
compromised patients and can also threaten healthy individuals.
For example, methicillin-resistant Staphylococcus aureus
(MRSA), vancomycin-resistant Enterococcus faecalis, and ampi-
cillin-resistant Escherichia coli have all become increasingly
common hospital-acquired infections (Aires de Sousa and de
Lencastre, 2003; Murray, 2000; Tomasz, 1994). The growing
threat of antibiotic-resistant bacteria thus confers a pressing
need for new antibiotics.
The growing problem of antibiotic-resistant bacteria raises the
question of how the AMPs of the mammalian intestine have
retained their efficacy over evolutionary timescales. A partial
answer to this question might lie in the fact that intestinal epithe-
lial cells deploy a diverse arsenal of AMPs, lowering the
likelihood of combined resistance. In addition, the targeting of
essential cell-wall or cell-membrane structures most likely also
contributes to the long-term effectiveness of endogenous
AMPs because bacteria generally cannot alter these structures
without compromising fitness.
Despite the sustained efficacy of barrier-surface AMPs,
numerous microorganisms have evolved mechanisms to evade
their action. Some pathogens, such as Staphylococcus aureus,
Salmonella enterica, and Legionella pneumophila, modify their
membranes with cationic substitutions to repulse basic AMPs
such as defensins (Gunn et al., 2000; Peschel et al., 1999; Robey
et al., 2001). Other pathogens, such as S. aureus and group A
streptococci, inactivate AMPs by proteolysis (Nyberg et al.,
2004; Sieprawska-Lupa et al., 2004). Shigella species actively34 Immunity 42, January 20, 2015 ª2015 Elsevier Inc.inhibit the synthesis of certain AMPs by the host (Islam et al.,
2001), and Listeria monocytogenes canmodify its peptidoglycan
to evade enzymatic cleavage by lysozyme (Boneca et al., 2007).
Harnessing Endogenous AMPs for Human Health
Because they do not readily induce bacterial resistance, endog-
enous AMPs offer tremendous promise as novel therapeutic
antibiotics. However, several properties of endogenous AMPs
pose barriers to the widespread development of AMPs as thera-
peutics (Peters et al., 2010). First, AMPs are highly susceptible to
proteolytic degradation by microbial and host enzymes and thus
can have relatively short half-lives. Second, many AMPs are also
toxic to eukaryotic cell membranes. As discussed above, defen-
sins, cathelicidins, and REG3 lectins can target host cell mem-
branes and must therefore be kept in check prior to secretion
by inhibitory propeptides. Thus, there are likely to be toxicity
problems if these proteins are used as therapeutics.
A number of these problems can be solved through protein-
engineering strategies. For example, AMP variants that are sta-
ble to enzymatic digestion can be created. Most AMPs that kill
bacteria through membrane disruption do so through direct in-
teractions with bacterial membranes rather than stereospecific
interactions with chiral receptors. Thus, the D-entantiomers of
these proteins permeabilize membranes as effectively as the
natural L-entantiomers and can be used as therapeutics with
longer half-lives (Toke, 2005). Likewise, the engineering of pep-
tidomimetics with altered numbers of charged amino acids has
the potential to reduce hydrophobicity and thus decrease
toxicity to host cells (Matsuzaki, 2009). Packaging natural
AMPs or their peptidomimetics and delivering them to the site
of action via nanoparticles can further reduce non-specific cyto-
toxicity and enhance stability (Hood et al., 2013). Using these
and other approaches, researchers are now working to develop
a number of endogenous AMPs as therapeutics. Many of these
peptidomimetics have potent bactericidal activity against
multi-drug-resistant bacteria while being stable to proteolysis
(Mendez-Samperio, 2014).
Larger AMPs, such as the REG3 lectins, offer unique opportu-
nities for engineering designer antimicrobial therapeutics. In the
case of the REG3 lectins, the amino acids thatmediate binding to
bacterial peptidoglycan are distinct from the protein domains
that promote membrane permeabilization (Lehotzky et al.,
2010;Mukherjee et al., 2014). Consequently, these two functions
can be uncoupled (Mukherjee et al., 2009). This suggests the
possibility of creating lectin variants where the carbohydrate-
binding domain is re-engineered to target specific bacterial
species or groupswhile retaining the intrinsicmembrane-perme-
abilization activity. Novel binding specificities could be evolved
against specific ligand structures through approaches such as
phage-display mutagenesis or directly engineered by replace-
ment of peptidoglycan-binding amino acids with sequences
that confer distinct carbohydrate-binding specificities. Such
approaches have the potential to guide the development of a
diverse array of novel antimicrobial therapeutics that can pre-
cisely target certain organisms.
AMP Dysfunction in Inflammatory Disease
Inflammatory bowel disease (IBD), a chronic inflammation of the
intestine, afflicts 0.1% of the population in North America and
Figure 3. AMP Dysfunction in Inflammatory Disease
The proteins NOD2, TCF4, XBP1, and ATG16L1 each promote AMP expres-
sion or secretion by Paneth cells. Polymorphisms in the genes encoding these
proteins are associated with increased risk for inflammatory bowel disease.
Although the exact mechanisms remain poorly understood, the increased risk
of disease could be due in part to reduced production of AMPs that normally
control host interactions with intestinal microbes. Abbreviations are as follows:
MDP, muramyl dipeptide; and ER, endoplasmic reticulum.
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Reviewnorthern Europe. Although the basic causes of IBD remain poorly
understood, dysregulated control of host-microbial interactions
is clearly involved in IBD pathogenesis (Xavier and Podolsky,
2007). As evidence of this, patients with IBD frequently have
increased numbers of bacteria associated with their intestinal
epithelial surfaces (Swidsinski et al., 2005), suggesting impair-
ment of the mechanisms that normally limit interactions between
the microbiota and host tissues.
Several key examples illustrate how genetic defects leading to
decreased AMP production can be associated with intestinal
inflammation and disease (Figure 3). The first IBD risk allele to
be identified was NOD2, which is associated with ileal Crohn’s
disease (a distinct type of IBD) (Hugot et al., 2001; Ogura et al.,
2001). In Crohn’s patients with the mutant NOD2 allele, severe
intestinal inflammation coincides with lowered a-defensin
expression (Wehkamp et al., 2005), suggesting that impaired
antimicrobial defense might contribute to disease pathology.
More recently, variations in the gene encoding the Wnt pathway
transcription factor TCF4, which controls a-defensin expression
(van Es et al., 2005), have been found to be associated with ileal
Crohn’s disease (Koslowski et al., 2009). Polymorphisms in the
gene encoding another component of the Wnt signaling path-
way, low-density lipoprotein receptor-related protein 6 (LRP6),
are also associated with ileal Crohn’s disease (Koslowski et al.,
2012). Although the underlying disease mechanisms remain un-
known, these findings suggest that mutations in NOD2, TCF4,
and LRP6 could lead to decreased a-defensin production and
consequent inflammation.
Two other Crohn’s disease risk alleles impact the Paneth cell
secretory pathway in the intestine and thus can impair AMPsecretion. ATG16L1 encodes a key protein of the autophagy
pathway, which regulates cellular-membrane recycling and ho-
meostasis. Mice with a hypomorphic Atg16l1 allele exhibit an
impaired Paneth-cell secretory pathway, resulting in decreased
AMP release (Cadwell et al., 2008). Similarly, individuals har-
boring a polymorphic variant of ATG16L1 exhibit abnormal Pan-
eth-cell granule formation and are at elevated risk for intestinal
inflammatory disease (Cadwell et al., 2008; VanDussen et al.,
2014). This suggests a disease model in which the human
ATG16L1 risk allele results in reduced AMP secretion and
thereby increases the likelihood of bacterial invasion and intesti-
nal inflammation. Finally, hypomorphic alleles of the gene encod-
ing the transcription factor X-box-binding protein 1 (XBP1) are
associated with IBD (Kaser et al., 2008). XBP1 is required for
normal development of secretory cells, and thus mice lacking
XBP1 have severe Paneth-cell dysfunction that is coincident
with spontaneous intestinal inflammation (Kaser et al., 2008).
Such Paneth-cell abnormalities could contribute to the in-
creased risk of IBD in individuals that harbor XBP1 variants.
Conclusions and Future Perspectives
The mammalian intestinal epithelium is faced with a continuous
and complex microbial challenge that is unique among tissues.
Epithelial cells cope with this challenge in part by producing a
diverse array of AMPs that rapidly kill or inactivate bacteria.
The emerging picture is that epithelial AMPs not only protect
against pathogen colonization and invasion but also shape the
composition and physical location of indigenous bacterial com-
munities. Fully illuminating how AMPs impact the microbial ecol-
ogy of the intestine will require further work.
Other body surfaces, such as the skin (Grice and Segre,
2011), respiratory tract (Dickson et al., 2013), and urogenital
tract (Ma et al., 2012), also harbor diverse assemblages of
commensal microorganisms. The epithelial cells lining these
surfaces also produce a diverse arsenal of AMPs that are
important for limiting pathogen colonization (Nizet et al., 2001)
and that probably also shape the composition of commensal
communities at these sites. Ongoing and future studies of
these tissues will therefore be essential for obtaining a compre-
hensive picture of how AMPs impact the microbial ecology of
body surfaces.
Finally, the majority of in vivo studies performed to date have
focused on intestinal AMP activities against bacteria. However,
the intestinal microbiota also includes eukaryotic viruses (Virgin,
2014), bacteriophages (Reyes et al., 2010), and eukaryotic or-
ganisms such as fungi (Iliev et al., 2012). It will be interesting to
determine how intestinal AMPs influence these other elements
of the microbial community, either directly by targeting of these
microbes or indirectly by affecting the bacterial communities of
the intestine. Ultimately, such efforts should yield deeper insight
into how mammalian hosts manage interactions with the micro-
bial world and should provide new strategies for improving hu-
man health.
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